128 related articles for article (PubMed ID: 17163840)
1. Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports.
King J; Thatcher N; Pickering C; Hasleton P
Histopathology; 2006 Dec; 49(6):561-8. PubMed ID: 17163840
[TBL] [Abstract][Full Text] [Related]
2. The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses.
Wolanski KD; Whitaker D; Shilkin KB; Henderson DW
Cancer; 1998 Feb; 82(3):583-90. PubMed ID: 9452278
[TBL] [Abstract][Full Text] [Related]
3. A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours.
Garcia-Prats MD; Ballestin C; Sotelo T; Lopez-Encuentra A; Mayordomo JI
Histopathology; 1998 May; 32(5):462-72. PubMed ID: 9639123
[TBL] [Abstract][Full Text] [Related]
4. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data.
King JE; Thatcher N; Pickering CA; Hasleton PS
Histopathology; 2006 Feb; 48(3):223-32. PubMed ID: 16430468
[TBL] [Abstract][Full Text] [Related]
6. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
Cury PM; Butcher DN; Corrin B; Nicholson AG
J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
[TBL] [Abstract][Full Text] [Related]
7. Comparison of silver-staining nucleolar organizer region (AgNOR) counts and proliferating cell nuclear antigen (PCNA) expression in reactive mesothelial hyperplasia and malignant mesothelioma.
Bethwaite PB; Delahunt B; Holloway LJ; Thornton A
Pathology; 1995 Jan; 27(1):1-4. PubMed ID: 7603742
[TBL] [Abstract][Full Text] [Related]
8. Differentiation of malignant from normal and reactive mesothelial cells by the argyrophil technique for nucleolar organiser region associated proteins.
Ayres JG; Crocker JG; Skilbeck NQ
Thorax; 1988 May; 43(5):366-70. PubMed ID: 2461601
[TBL] [Abstract][Full Text] [Related]
9. How to assess the best immunohistochemical panel in the diagnosis of malignant pleural mesothelioma in a pathology lab.
Mlika M; Lamzibri O; Bacha S; Laabidi S; Haddouchi C; Mezni FE
J Immunoassay Immunochem; 2018; 39(3):263-273. PubMed ID: 29757709
[TBL] [Abstract][Full Text] [Related]
10. [Study on diagnostic value of analyzing argyrophilic nucleolar organizer regions in benign and malignant pleural effusions].
Jiang S; Zeng Z; Liao Z
Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):34-6. PubMed ID: 11263298
[TBL] [Abstract][Full Text] [Related]
11. The usefulness of CYFRA 21-1 in diagnosing and monitoring malignant pleural mesothelioma.
Marukawa M; Hiyama J; Shiota Y; Ono T; Sasaki N; Taniyama K; Mashiba H
Acta Med Okayama; 1998 Apr; 52(2):119-23. PubMed ID: 9588228
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical panel for distinction between squamous cell carcinoma, adenocarcinoma and mesothelioma.
Pritchard SA; Howat AJ; Edwards JM
Histopathology; 2003 Aug; 43(2):197-9. PubMed ID: 12877739
[No Abstract] [Full Text] [Related]
13. The role of immunohistochemical evaluation in the diagnosis of malignant mesothelioma of the pleura.
Panjković M; Lovrenski A; Eri Z; Usaj SK; Tegeltija D; Krcedinac J
Vojnosanit Pregl; 2013 Nov; 70(11):1010-4. PubMed ID: 24397195
[TBL] [Abstract][Full Text] [Related]
14. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of AgNOR score in differentiating benign from malignant pulmonary aspiration cytology.
Chern JH; Lee YC; Yang MH; Chang SC; Perng RP
Acta Cytol; 1997; 41(2):393-8. PubMed ID: 9100772
[TBL] [Abstract][Full Text] [Related]
16. [Utility of morphometry and nucleolar organizer regions count in the differentiation of reactive and malignant mesothelial cells in pleural effusions].
Colecchia M; Agnelli T; Caronni E; Leopardi O
Pathologica; 1991; 83(1083):89-97. PubMed ID: 1866205
[TBL] [Abstract][Full Text] [Related]
17. [Significance of FCM-DNA ploidy pattern, AgNOR counting, hTERT and PCNA expression in differentiating malignant from benign serous effusion].
Wu LY; Liu BR; Lu J; Ling MD; Chen J; Li P; Jiang Y
Ai Zheng; 2007 Feb; 26(2):178-82. PubMed ID: 17298749
[TBL] [Abstract][Full Text] [Related]
18. [Immunohistochemistry of mesotheliomas. Technique and current diagnostic contribution of immunohistochemical markers. General review].
Galateau-Salle F
Arch Anat Cytol Pathol; 1993; 41(5-6):212-22. PubMed ID: 8135582
[TBL] [Abstract][Full Text] [Related]
19. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma.
Betta PG; Magnani C; Bensi T; Trincheri NF; Orecchia S
Arch Pathol Lab Med; 2012 Mar; 136(3):253-61. PubMed ID: 22372901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
